Concert Bio

Founded in 2021 by Dr. Paul Rutten, Concert Bio is a biotechnology company developing beneficial microbes to enhance plant growth for hydroponic greenhouse growers. The company operates in the controlled environment agriculture (CEA) market, addressing the microbial imbalance that occurs when plants are grown outside of traditional soil environments. By reintroducing specific microbes, Concert Bio aims to improve crop yield, disease resistance, and even taste.

Concert Bio's business model revolves around its proprietary platform, which leverages the world's largest database of hydroponic microbiome data. Using machine learning models, the company identifies and develops tailored microbial products for crops in soilless systems. Its first product, Overture™, has demonstrated an average yield improvement of 9.9% across multiple crops in commercial grower trials. The company provides monitoring and analytical services to its clients, which include leading greenhouse growers across Europe.

The company is headquartered in London, UK, with lab facilities at the Imperial College Translation and Innovation Hub and plant research facilities in Penryn and at the Warwick University Innovation Campus. Concert Bio has secured funding from investors including The Venture Collective, Nucleus Capital, and Innovate UK, with a pre-seed round of $1.7 million in August 2022. As of late 2024 and early 2025, the company is moving from a research and development phase toward commercialization, with plans to launch its products at scale.

Keywords: beneficial microbes, hydroponics, controlled environment agriculture, agtech, plant microbiome, microbial biostimulants, soilless agriculture, greenhouse growers, yield improvement, sustainable agriculture, microbiome database, machine learning, Overture, Paul Rutten, agricultural biotechnology, crop performance, data science, sustainable farming, vertical farming, food technology